Results 51 to 60 of about 981,818 (305)

"Recurrent Non-Typhoidal Salmonella Bacteremia in a Patient with Interleukin -12p40 Deficiency "

open access: yesIranian Journal of Allergy, Asthma and Immunology, 2004
The South eastern region of Iran is an endemic area for salmonellosis. Sometimes bacteremia due to nontyphoidal salmonella occurs but certain patients are at increased risk for recurrent bacteremia.
Batool Sharifi Mood   +11 more
doaj  

A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard Study [PDF]

open access: yes, 2006
Objective: The objective of the trial was to evaluate in a pilot setting the safety and efficacy of interleukin-2 (IL-2) therapy when used without concomitant antiretroviral therapy as a treatment for HIV infection.
Abrams   +44 more
core   +2 more sources

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

open access: yesMolecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed   +10 more
wiley   +1 more source

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

open access: yesMolecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra   +10 more
wiley   +1 more source

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date. [PDF]

open access: yes, 2018
Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in the United States. Advances over the past 20 years in understanding the immune-mediated pathophysiology of psoriasis have led to the development of targeted biologic
Beck, Kristen M   +3 more
core  

Validation of an automated enzyme immunoassay for interleukin-6 for routine clinical use [PDF]

open access: yes, 1998
Serum levels of Interleukin-6 (IL-6), a proinflammatory cytokine, are increased in early stages of inflammatory diseases such as infection and sepsis. Assay systems which permit its measurement within a few hours and as a single measurement have not been
Cremer, Peter   +8 more
core   +1 more source

Strength through diversity: how cancers thrive when clones cooperate

open access: yesMolecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken   +3 more
wiley   +1 more source

Zirconium oxide nanoparticles: Protocolicidal effect against hydatid cyst protoscoleces with interleukins evaluation in mice [PDF]

open access: yesIraqi Journal of Veterinary Sciences
The current study investigated the effect of zirconium oxide nanoparticles NPs on the levels of interleukins in mice inoculated with protoscoleces of Echinococcus granulosus, after exposure to ZrO2 NPs at the doses,5,10,50, and 100 µg /ml for 30 ...
Zina A. Mahmoud   +2 more
doaj   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

open access: yesMolecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken   +7 more
wiley   +1 more source

Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy

open access: yesDrug Design, Development and Therapy, 2016
Parakkal Deepak, Edward V Loftus Jr Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA Abstract: Crohn’s disease is characterized by a dysregulation of both innate and adaptive immunity responses ...
Deepak P, Loftus EV Jr
doaj  

Home - About - Disclaimer - Privacy